Supernus Pharmaceuticals, Inc.
SUPN
$56.50
$0.821.47%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.55% | 11.82% | 8.94% | 6.79% | -0.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.55% | 11.82% | 8.94% | 6.79% | -0.61% |
| Cost of Revenue | 3.84% | 0.96% | -7.01% | -17.99% | -21.34% |
| Gross Profit | 5.77% | 13.42% | 11.49% | 10.91% | 2.98% |
| SG&A Expenses | 4.56% | 1.73% | -0.32% | 1.79% | -6.21% |
| Depreciation & Amortization | -5.11% | -5.97% | -5.35% | -1.48% | 1.40% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.00% | 2.89% | 0.98% | 1.11% | -4.36% |
| Operating Income | 28.05% | 950.62% | 361.51% | 132.63% | 130.56% |
| Income Before Tax | 119.55% | 1,628.66% | 3,434.49% | 96.32% | 40.77% |
| Income Tax Expenses | -45.11% | 214.45% | 1,552.10% | 13.00% | 292.02% |
| Earnings from Continuing Operations | 1,131.09% | 499.24% | 5,512.84% | 133.05% | -87.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,131.09% | 499.24% | 5,512.84% | 133.05% | -87.91% |
| EBIT | 28.05% | 950.62% | 361.51% | 132.63% | 130.56% |
| EBITDA | 5.64% | 53.54% | 44.79% | 30.94% | 23.69% |
| EPS Basic | 1,146.57% | 496.09% | 5,171.26% | 128.26% | -88.33% |
| Normalized Basic EPS | 34.41% | 472.96% | 260.25% | 120.97% | 113.01% |
| EPS Diluted | 1,219.17% | 478.63% | 14,025.26% | 168.90% | -87.91% |
| Normalized Diluted EPS | 33.64% | 474.02% | 275.60% | 157.95% | 168.81% |
| Average Basic Shares Outstanding | 1.58% | 1.33% | 1.03% | 0.91% | 1.04% |
| Average Diluted Shares Outstanding | 1.68% | 1.83% | -1.34% | -4.70% | -5.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |